About Pivotal Therapeutics
Pivotal Therapeutics is a publicly listed company based in Vaughan (Canada) founded in 2010 by George Jackowski and Rachelle MacSweeney. Purified Omega-3 therapies for cardiovascular disease are developed in Canada. Its chief executive, as recorded, is Rachelle MacSweeney. Its focus areas include Life Sciences, Nutraceuticals Tech, Functional Foods and Beverages and Cardiac and Vascular Disorders.
Company details
Pivotal Therapeutics is a Canadian, commercial-stage biopharma developing highly-purified prescription Omega 3 Therapy for CVD. In Feb 2016, it announced US patent for stabilization of vulnerable plaque using a combination of statin and Omega 3 fatty acids. The company has one prescription product and 2 OTC products. The prescription product is VASCAZEN, indicated for Omega-3 Deficiency in cardiovascular patients. The product was clinically shown to correct an Omega-3 Deficiency in CVD Patients, with an associated 48 reduction in triglycerides and a rise in HDL-C without negative impact on the LDL-C lipid profile in the 8-week treatment period. The 2 OTC Products are OMAZEN and BENEFISHIAL.
- Headquarters Vaughan, Canada
- Founders George Jackowski, Rachelle MacSweeney
- Stage Public
- SectorsHealthcare
- Website pivotaltherapeutics.us
- Social LinkedIn X
- Latest Funding Round$7.7M (USD), Debt – Conventional
Mar 2014
Funding Insights of Pivotal Therapeutics
- Total Rounds 1
- Last Round Debt – Conventional — $7.7M
- First Round $7.7M
(Mar 2014)
All 1 funding rounds of Pivotal Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2014 | $7.7M | Debt – Conventional | – | – | – |
People of Pivotal Therapeutics
2 people are tracked at Pivotal Therapeutics (2 in leadership).
| Name | Role | Group |
|---|---|---|
George Jackowski | Co-Founder & CSO | Leadership |
Rachelle MacSweeney | Co-Founder, President and Chief Executive Officer | Leadership |
Complete people profiles for Pivotal Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pivotal Therapeutics
3 dated milestones of Pivotal Therapeutics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Pivotal Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $7.7M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Pivotal Therapeutics
Pivotal Therapeutics was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Pivotal Therapeutics is headquartered in Vaughan, Canada. It is registered at Vaughan, Ontario, Canada.
Rachelle MacSweeney is the CEO of Pivotal Therapeutics, as recorded in our data. They have also founded this company.
Pivotal Therapeutics is a Canadian, commercial-stage biopharma developing highly-purified prescription Omega 3 Therapy for CVD. In Feb 2016, it announced US patent for stabilization of vulnerable plaque using a combination of statin and Omega 3 fatty acids. The company has one prescription product and 2 OTC products. The prescription product is VASCAZEN, indicated for Omega-3 Deficiency in cardiovascular patients. The product was clinically shown to correct an Omega-3 Deficiency in CVD Patients, with an associated 48 reduction in triglycerides and a rise in HDL-C without negative impact on the LDL-C lipid profile in the 8-week treatment period. The 2 OTC Products are OMAZEN and BENEFISHIAL.